Jim Cramer's top 10 things to watch in the stock market Friday

Nasdaq futures were down more than 2.5%, with Intel falling over 25% premarket after weak guidance and Amazon down nearly 7%; Reddit dropped more than 21% after weak fourth-quarter guidance. The article also flags Alphabet’s AI and Search monetization concerns and Marvell’s further 6% decline, while noting positive earnings and outlooks at Starbucks, Centene and AstraZeneca; AstraZeneca shares rose 6%.

Analysis

Treat the selloff as a dispersion event, not proof of a durable Nasdaq bear market: a futures gap can amplify de-risking, but the more investable signal is widening divergence between businesses with measurable demand and those whose AI monetization or economics remain unproven. Near term, avoid catching INTC immediately after a severe gap. The memory-cost exposure described is a potential margin headwind for PC economics, while SK hynix could retain pricing leverage if tight HBM supply persists; verify Intel's guidance and product-level exposure before sizing either side.

AMZN's AWS growth outlook supports the revenue case, but rising capex can defer free-cash-flow conversion. The market may be underpricing that trade-off even if cloud growth holds. GOOG faces a more structural risk: AI answers could weaken search monetization, but replacing or combining Search with Gemini is speculation, not a demonstrated fix. META may be a relative beneficiary if advertiser demand remains resilient, though RDDT's search-traffic warning is not evidence that all ad platforms share the same exposure.

MRVL acquisition chatter is not a thesis by itself. A deal for Lumentum or Coherent could add capability but also introduce financing, integration, and execution risk; don't price a takeover premium without confirmation. SBUX and AZN have constructive company-specific narratives, but validate comparable sales/margins and pipeline progress rather than extrapolating one quarter. Over 6–18 months, biotech catalysts and cloud capex productivity matter more than today's defensiveness. The contrarian risk: indiscriminate selling may create relative-value opportunities, but calling a broad-market bottom from one morning's price action is premature.

Key Decisions for Investors

• Near term, keep broad tech beta modest rather than making a high-conviction index short from futures alone. Reassess if selling broadens beyond megacap technology or earnings revisions deteriorate; a rapid stabilization in breadth would falsify the immediate de-risking case.
• Prefer a conditional relative-value position: long META versus short GOOG, sized small until ad trends and search monetization are clearer. The thesis is relative exposure to AI-driven search disruption, not that META is immune; cut it if META ad growth weakens or GOOG demonstrates durable AI-search monetization.
• Do not chase INTC downside after the gap. Wait for updated guidance and evidence on PC gross-margin sensitivity to memory costs; continued estimate cuts would support staying underweight, while stable margins and credible product execution would invalidate that view.
• For MRVL, treat any Lumentum/Coherent deal as an event-risk watch, not an assumed catalyst. Revisit only after terms, funding, and expected returns are disclosed; avoid paying for an unconfirmed acquisition narrative.
• Use SBUX, AZN, CNC, or LLY as selective diversifiers only where valuation and upcoming operating or clinical/regulatory catalysts support the risk. For SBUX, track comparable sales and margin delivery; for AZN, verify trial and regulatory milestones. A defensive label alone is not a reason to add.